373 related articles for article (PubMed ID: 33077661)
1. Investigational Antiviral Therapy Models for the Prevention and Treatment of Congenital Cytomegalovirus Infection during Pregnancy.
Hamilton ST; Marschall M; Rawlinson WD
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077661
[TBL] [Abstract][Full Text] [Related]
2. Human cytomegalovirus utilises cellular dual-specificity tyrosine phosphorylation-regulated kinases during placental replication.
Hamilton ST; Hutterer C; Egilmezer E; Steingruber M; Milbradt J; Marschall M; Rawlinson WD
Placenta; 2018 Dec; 72-73():10-19. PubMed ID: 30501876
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
5. Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Oiknine-Djian E; Bar-On S; Laskov I; Lantsberg D; Haynes RK; Panet A; Wolf DG
Antiviral Res; 2019 Dec; 172():104639. PubMed ID: 31654672
[TBL] [Abstract][Full Text] [Related]
6. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Frange P; Leruez-Ville M
Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta.
Tabata T; Petitt M; Zydek M; Fang-Hoover J; Larocque N; Tsuge M; Gormley M; Kauvar LM; Pereira L
J Virol; 2015 May; 89(9):5134-47. PubMed ID: 25741001
[TBL] [Abstract][Full Text] [Related]
8. Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.
Faure Bardon V; Peytavin G; Lê MP; Guilleminot T; Elefant E; Stirnemann J; Leruez-Ville M; Ville Y
PLoS One; 2020; 15(4):e0232140. PubMed ID: 32353010
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo model of congenital cytomegalovirus infection and new combination therapies.
Morère L; Andouard D; Labrousse F; Saade F; Calliste CA; Cotin S; Aubard Y; Rawlinson WD; Esclaire F; Hantz S; Ploy MC; Alain S
Placenta; 2015 Jan; 36(1):41-7. PubMed ID: 25479789
[TBL] [Abstract][Full Text] [Related]
10. APOBEC3A Is Upregulated by Human Cytomegalovirus (HCMV) in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector.
Weisblum Y; Oiknine-Djian E; Zakay-Rones Z; Vorontsov O; Haimov-Kochman R; Nevo Y; Stockheim D; Yagel S; Panet A; Wolf DG
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956761
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Piret J; Goyette N; Boivin G
Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
[TBL] [Abstract][Full Text] [Related]
12. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.
Drouot E; Piret J; Boivin G
Antivir Ther; 2016; 21(6):535-539. PubMed ID: 26844400
[TBL] [Abstract][Full Text] [Related]
13. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
[TBL] [Abstract][Full Text] [Related]
14. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation.
El Helou G; Razonable RR
Expert Opin Drug Saf; 2019 Nov; 18(11):1017-1030. PubMed ID: 31478398
[No Abstract] [Full Text] [Related]
15. The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication.
Oiknine-Djian E; Weisblum Y; Panet A; Wong HN; Haynes RK; Wolf DG
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712656
[TBL] [Abstract][Full Text] [Related]
16. Antiviral Treatment of Maternal and Congenital Cytomegalovirus (CMV) Infections.
Pinninti S; Boppana S
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896892
[TBL] [Abstract][Full Text] [Related]
17. An overview of letermovir: a cytomegalovirus prophylactic option.
Gerna G; Lilleri D; Baldanti F
Expert Opin Pharmacother; 2019 Aug; 20(12):1429-1438. PubMed ID: 31282759
[No Abstract] [Full Text] [Related]
18. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication.
Wildum S; Zimmermann H; Lischka P
Antimicrob Agents Chemother; 2015; 59(6):3140-8. PubMed ID: 25779572
[TBL] [Abstract][Full Text] [Related]
19. Small Molecules-Prospective Novel HCMV Inhibitors.
Bogner E; Egorova A; Makarov V
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809292
[TBL] [Abstract][Full Text] [Related]
20. Antiviral treatment of cytomegalovirus infection: an update.
Härter G; Michel D
Expert Opin Pharmacother; 2012 Apr; 13(5):623-7. PubMed ID: 22299626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
